| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
MCB-3681 targets gram-positive bacteria. As the active substance of the antibacterial agent Oxaquin, MCB-3681 is the antimicrobial active form of Oxaquin that is active against gram-positive bacteria. The compound specifically targets and exhibits activity against gram-positive bacteria. MCB-3681 is resistant to gram-positive bacteria, indicating that it is effective against this class of pathogens. However, the specific molecular target of MCB-3681 within gram-positive bacteria (such as cell wall synthesis, protein synthesis, or DNA replication) has not been clearly identified in the available literature. The compound's mechanism of action is likely related to its antibacterial activity, but further characterization is needed to establish its precise target and mode of action.
|
|---|---|
| ln Vitro |
MCB-3681 demonstrates potent in vitro antibacterial activity against gram-positive bacteria. As the active substance of Oxaquin, MCB-3681 is the antimicrobial active form that is active against gram-positive bacteria. The compound specifically targets and exhibits activity against gram-positive bacteria, indicating its effectiveness against this class of pathogens. MCB-3681 has a purity of 99.23%, ensuring consistent activity in antibacterial assays. The compound's in vitro activity has been characterized in antibacterial susceptibility tests, where it has shown efficacy against various gram-positive bacterial strains. However, specific IC₅0 or MIC values, as well as the range of bacterial species tested, have not been extensively reported in the available literature. Further characterization is needed to establish the compound's full antibacterial spectrum.
|
| ln Vivo |
In vivo activity data for MCB-3681 are limited. As the active substance of the antibacterial agent Oxaquin, MCB-3681 has the potential to exert antibacterial effects in vivo against gram-positive bacterial infections. However, comprehensive pharmacokinetic and pharmacodynamic studies in animal models have not been extensively reported in the available literature. The compound is the antimicrobial active form of Oxaquin that is active against gram-positive bacteria, suggesting that it may be effective in animal models of gram-positive bacterial infections. Further research is needed to establish the compound's in vivo efficacy, dosing regimens, and safety profile. The compound has a molecular weight of 626.60 and a molecular formula of C31H32F2N4O₈.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for MCB-3681 is not well-established in the literature, as the compound is primarily studied for its antibacterial activity rather than specific enzyme or receptor inhibition. Typical antibacterial susceptibility testing involves culturing gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, or Enterococcus species) in appropriate growth media and exposing them to varying concentrations of MCB-3681 (typically 0.1-100 ug/mL). The minimum inhibitory concentration (MIC) is determined by broth microdilution or agar dilution methods according to CLSI guidelines. The compound's antibacterial activity is assessed by measuring bacterial growth inhibition after 18-24 hours of incubation at 37degC. The MIC is defined as the lowest concentration of the compound that inhibits visible bacterial growth. The compound has a purity of 99.23%.
|
| Cell Assay |
The in vitro cell-based assay for MCB-3681 is not applicable in the traditional sense, as the compound is an antibacterial agent that targets bacteria rather than mammalian cells. However, antibacterial susceptibility testing is performed using bacterial cultures rather than mammalian cell lines. Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, or Enterococcus species) are cultured in appropriate growth media (such as Mueller-Hinton broth) and exposed to varying concentrations of MCB-3681 (0.1-100 ug/mL) in 96-well plates. After 18-24 hours of incubation at 37degC, bacterial growth is assessed by measuring optical density at 600 nm or by viable colony counting. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth. The compound has a molecular weight of 626.60.
|
| Animal Protocol |
In vivo animal studies for MCB-3681 have not been extensively documented in the literature. Based on the compound's mechanism as the active substance of the antibacterial agent Oxaquin, potential animal studies would typically involve administration of the compound via oral, intravenous, or subcutaneous routes in rodent models of gram-positive bacterial infections. Dosing would be determined based on preliminary pharmacokinetic data and solubility profiles. Common endpoints in such studies would include evaluation of bacterial clearance from infected tissues (such as blood, lung, or skin), assessment of survival rates, and monitoring of general toxicity parameters. However, comprehensive in vivo efficacy and toxicity studies have not been widely reported for this compound. The compound has a molecular formula of C31H32F2N4O₈ and a molecular weight of 626.60.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MCB-3681 have not been characterized in the literature. The compound has a molecular weight of 626.60 g/mol and a molecular formula of C31H32F2N4O₈. It has a purity of 99.23%. The compound is the active substance of the antibacterial agent Oxaquin and is the antimicrobial active form that is active against gram-positive bacteria. However, detailed pharmacokinetic parameters such as half-life, bioavailability, clearance, and volume of distribution have not been reported. The compound's physicochemical properties, including its lipophilicity and solubility, would influence its absorption, distribution, metabolism, and excretion profile. Further research is needed to characterize the compound's pharmacokinetic properties.
|
| Toxicity/Toxicokinetics |
MCB-3681 (CAS#: 790704-42-6) is a research-grade antibacterial compound with the molecular formula C31H32F2N4O₈ and a molecular weight of 626.60. This compound is the active substance of the antibacterial agent Oxaquin and is known for its efficacy against gram-positive bacteria. MCB-3681 is the antimicrobial active form of Oxaquin that is active against gram-positive bacteria and is resistant to gram-positive bacteria, indicating its effectiveness against this class of pathogens. The compound specifically targets and exhibits activity against gram-positive bacteria. MCB-3681 has a purity of 99.23% and is intended for research purposes only. No clinical trials or regulatory approvals have been reported for this compound.
|
| References |
| Molecular Formula |
C31H32F2N4O8
|
|---|---|
| Molecular Weight |
626.604595184326
|
| Exact Mass |
626.218
|
| CAS # |
790704-42-6
|
| PubChem CID |
11273606
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
45
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C1C(C(=O)O)=CN(C2CC2)C2C=C(N3CCC(O)(COC4C=CC(N5C(=O)O[C@@H](CNC(=O)C)C5)=CC=4F)CC3)C(=CC1=2)F
|
| InChi Key |
YEDRNPDLVCNIAV-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C31H32F2N4O8/c1-17(38)34-13-20-14-37(30(42)45-20)19-4-5-27(24(33)10-19)44-16-31(43)6-8-35(9-7-31)26-12-25-21(11-23(26)32)28(39)22(29(40)41)15-36(25)18-2-3-18/h4-5,10-12,15,18,20,43H,2-3,6-9,13-14,16H2,1H3,(H,34,38)(H,40,41)/t20-/m0/s1
|
| Chemical Name |
7-[4-[[4-[(5S)-5-(acetamidomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenoxy]methyl]-4-hydroxypiperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~99.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5959 mL | 7.9796 mL | 15.9591 mL | |
| 5 mM | 0.3192 mL | 1.5959 mL | 3.1918 mL | |
| 10 mM | 0.1596 mL | 0.7980 mL | 1.5959 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
